(Photo Courtesy: www.d3eksha.com)
The global treatment market for Duchenne Muscular Dystrophy (DMD) will expand in value at a staggering Compound Annual Growth Rate (CAGR) of 160.5 percent, from approximately $8.2 million in 2014 to $990 million by 2019, says research and consulting firm GlobalData.
The company's latest report states that this growth will occur across six major markets: the US, France, Germany, Italy, Spain and the UK.
Combined, the five European countries will contribute 55.2 percent to the total market value by 2019, while the US will account for 44.8 percent.
According to Dr Nikhilesh Sanyal, GlobalData's analyst covering immunology, the primary driver behind this impressive expansion will be the market entry of PTC Therapeutics' Translarna, Sarepta Therapeutics' eteplirsen, and BioMarin/Prosensa's drisapersen.
Dr Sanyal says: "These mutation-specific drugs are expected to have a high price point due to their novelty, efficacy and orphan drug status, and will contribute 85.6 percent to the DMD treatment arena by 2019. While Translarna is expected to be the top-selling DMD drug by 2019, exon-51-skipping therapies drisapersen and eteplirsen will also be a hotspot for growth, thanks to their rapid clinical development and significant demand.